ProKidney

PROK

Market cap $296M

2.16 USD

+0.07

3.35%

At close Updated Feb 23, 4:00 PM EST

Pre-market

After hours

2.11

-0.05

2.31%

1 day

3.35%

5 days

8.54%

1 month

-0.46%

3 months

0.93%

6 months

-8.09%

Year to date

-3.14%

1 year

44%

5 years

-78.64%

10 years

-78.64%

About: ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

Employees: 204

Healthcare Biotechnology